Pravastatin in diabetes-associated hypercholesterolemia
| Autor: | P. F. M. J. Spooren, J. A. Schouten, J.J. van Doormaal, E. N. W. Janssens, C. Rustemeijer |
|---|---|
| Přispěvatelé: | Faculteit Medische Wetenschappen/UMCG |
| Rok vydání: | 1998 |
| Předmět: |
Adult
Male medicine.medical_specialty Time Factors ARTERY DISEASE Endocrinology Diabetes and Metabolism Hypercholesterolemia Blood lipids CORONARY HEART-DISEASE chemistry.chemical_compound MELLITUS Endocrinology Diabetes mellitus Internal medicine Internal Medicine Medicine Humans SERUM-CHOLESTEROL Aged Pravastatin RISK business.industry Cholesterol LONG-TERM TREATMENT Anticholesteremic Agents nutritional and metabolic diseases MEN General Medicine Middle Aged medicine.disease Lipid Metabolism Hydroxymethylglutaryl-CoA reductase Lipids SIMVASTATIN LIPOPROTEIN Diabetes Mellitus Type 1 chemistry Diabetes Mellitus Type 2 Simvastatin SAFETY diabetes mellitus lipids (amino acids peptides and proteins) Female business Dyslipidemia medicine.drug Lipoprotein |
| Zdroj: | Acta diabetologica, 34(4), 294-300. SPRINGER-VERLAG ITALIA SRL |
| ISSN: | 0940-5429 |
| Popis: | Patients with diabetes mellitus (DM), type 1 and type 2, have an increased risk of coronary heart disease as a result of accelerated atherosclerosis. Dyslipidemia, often found in these patients, plays an important role in this process. This study investigates the efficacy and safety of lipid-lowering therapy with pravastatin, a 3-HMG-Coenzym A reductase inhibitor in hypercholesterolemic type-1 and type-2 diabetic patients. Of 49 patients (22 type-1 DM and 27 type-2 DM), 24 patients were treated with pravastatin, 20 mg/day, and 25 patients with placebo. After 24 weeks, total cholesterol (TC) was decreased by 22.2%, low-density lipoprotein (LDL) cholesterol by 25.8% and triglycerides (TG) by 13.6%. Pravastatin treatment did not induce a significant change in high-density (HDL) cholesterol levels. No differences in effects of pravastatin treatment on serum lipids and lipoproteins were found with respect to the diabetes type. No serious side effects occurred and pravastatin treatment did not cause any deterioration in glycemia control. The data suggest that pravastatin is effective and safe in the treatment of dyslipidemia in both type-1 and type-2 diabetic patients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink